Comparing Rituximab vs Treanda
Rituximab | Treanda (bendamustine) |
|
---|
Rituximab | Treanda (bendamustine) |
|
---|---|---|
Prescription only
Rituximab (brand name Rituxan) is a CD20 monoclonal antibody that causes B-cells to self-destruct or disintegrate and may be used to treat Non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia... View more |
Prescription only
Treanda is a cytotoxic agent that must be administered by a health professional and may be used to treat chronic lymphocytic leukemia (CLL) and a certain type of non-Hodgkin lymphoma. It can cause... View more |
Related suggestions Non-Hodgkin's Lymphoma
|
More about Rituximab | More about Treanda (bendamustine) | |
Ratings & Reviews | ||
Rituximab has an average rating of 7.7 out of 10 from a total of 175 ratings on Drugs.com. 69% of reviewers reported a positive effect, while 14% reported a negative effect. |
Treanda has an average rating of 9.0 out of 10 from a total of 1 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
|
Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||
View all Rituximab side effects |
View all Treanda side effects |
|
Drug Class | ||
Generic Availability | ||
N/A |
||
Pricing and Coupons * Prices are without insurance | ||
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
|
Dosage Forms | ||
N/A |
|
|
Brand Names | ||
Riabni, Rituxan, Ruxience, Truxima | Other bendamustine brands include: Belrapzo, Bendeka, Vivimusta | |
Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||
59.8 hours |
N/A |
|
CSA Schedule 1 View glossary of CSA terms | ||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
|
Pregnancy Category | ||
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
|
Drug Interactions | ||
A total of 197 drugs are known to interact with Rituximab:
|
A total of 298 drugs are known to interact with Treanda:
|
|
Alcohol/Food/Lifestyle Interactions | ||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
Disease Interactions | ||
First Approval Date | ||
N/A |
October 31, 2008 |
|
WADA Class View classifications | ||
N/A |
N/A |
|
More Information | ||
Patient Resources | ||
Professional Resources | ||
Related Treatment Guide | ||
|
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Rituxan
Rituxan is used to treat certain leukemias and lymphomas and some non-cancer conditions, such as ...
Monjuvi
Monjuvi is used to treat diffuse large B-cell lymphoma (DLBCL) in combination with lenalidomide ...
Truxima
Truxima is used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid ...
Breyanzi
Breyanzi is a CAR T cell therapy for large B-cell lymphoma, CLL/SLL, follicular lymphoma, mantle ...
Kymriah
Kymriah is used to treat B-cell precursor acute lymphoblastic leukemia (ALL), large B-cell ...
Polivy
Polivy (polatuzumab vedotin-piiq) is a targeted treatment that may be used to treat diffuse large ...
Yescarta
Yescarta is used to treat large B-cell lymphoma and follicular lymphoma (FL) in adults. It is a p ...
Zynlonta
Zynlonta (loncastuximab tesirine) is used to treat relapsed or refractory diffuse large B-cell ...
Xpovio
Xpovio is used to treat multiple myeloma (MM) or relapsed/refractory diffuse large B-cell lymphoma ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.